Abstract
TPS9093 Background: Combined BRAF and MEK inhibition yields improved response rates and overall survival compared with BRAF inhibitor monotherapy in BRAF mutant melanoma patients(Robert et al., 201...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have